Adage Capital Partners GP L.L.C. Buys Shares of 500,000 REGENXBIO Inc. (NASDAQ:RGNX)

Adage Capital Partners GP L.L.C. purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 500,000 shares of the biotechnology company's stock, valued at approximately $3,865,000. Adage Capital Partners GP L.L.C. owned about 1.01% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares in the last quarter. Norges Bank acquired a new position in REGENXBIO during the 4th quarter worth approximately $3,474,000. Voss Capital LP acquired a new stake in REGENXBIO in the fourth quarter valued at approximately $2,573,000. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after buying an additional 296,700 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of REGENXBIO during the fourth quarter worth $2,097,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Leerink Partners set a $24.00 target price on REGENXBIO in a research report on Tuesday, March 18th. Finally, HC Wainwright decreased their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, March 17th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.63.

REGENXBIO Trading Up 5.8 %

REGENXBIO stock traded up $0.57 during midday trading on Friday, reaching $10.40. The stock had a trading volume of 1,015,830 shares, compared to its average volume of 822,267. The company has a fifty day moving average price of $7.16 and a two-hundred day moving average price of $8.11. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $17.52. The company has a market capitalization of $521.22 million, a P/E ratio of -2.07 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, equities research analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.